USC.edu
Are You a Patient?

Saul J Priceman

Visiting Associate Professor of Medicine

Director of the KSOM/NCCC Center for Cancer Cellular Immunotherapy Research

Image of Saul J Priceman
Websites
Is this your profile? Click to edit
Email priceman@usc.edu
CTSI Profile

Overview

Dr. Saul Priceman is an Associate Professor in the Department of Medicine at USC, and the Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research. Over the last 14 years, his research has focused on T cell immunobiology and cancer immunotherapies. Dr. Priceman’s laboratory develops CAR T cell therapies and combinatorial approaches for the treatment of solid cancers, bringing several therapies to phase 1 clinical testing. His research has led to high-impact publications in Nature Medicine, Science Translational Medicine, Nature Communications, and Cell Metabolism, with numerous patents and technologies licensed for further clinical development. Dr. Priceman’s research has been funded with grants from the National Cancer Institute, Department of Defense, California Institute for Regenerative Medicine, and the Prostate Cancer Foundation. He received his B.S. in microbiology at UCSB, his Ph.D. in molecular and medical pharmacology at UCLA, and his postdoctoral research at City of Hope.

Publications

  • Multi-Omic Characterization of Single Cells and Cell-Free Components Detected in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease Cancers (Basel). 2024 Nov 06; 16(22). . View in PubMed
  • Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells Mol Ther Oncol. 2024 Jun 20; 32(2):200789. . View in PubMed
  • PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial Nat Med. 2024 Jun; 30(6):1636-1644. . View in PubMed
  • Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor J Am Coll Surg. 2024 Apr 01; 238(4):436-447. . View in PubMed
  • Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Ra expression Mol Ther. 2024 Feb 07; 32(2):527-539. . View in PubMed
  • Regulation of nuclear transcription by mitochondrial RNA in endothelial cells Elife. 2024 Jan 22; 13. . View in PubMed
  • Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies Cancers (Basel). 2023 Nov 30; 15(23). . View in PubMed
  • Res Sq. 2023 Oct 23. . View in PubMed
  • Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting bioRxiv. 2023 Jan 07. . View in PubMed
  • Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases J Immunother Cancer. 2023 04; 11(4). . View in PubMed
  • Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy Nat Commun. 2023 04 11; 14(1):2041. . View in PubMed
  • Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting Nat Commun. 2023 08 07; 14(1):4737. . View in PubMed
  • Advancing together and moving forward: Combination gene and cellular immunotherapies Mol Ther Oncolytics. 2022 Jun 16; 25:330-334. . View in PubMed
  • J Immunother Cancer. 2022 06; 10(6). . View in PubMed
  • Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer Gastroenterology. 2022 04; 162(4):1319-1333. . View in PubMed
  • Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer JCO Precis Oncol. 2022 03; 6:e2100239. . View in PubMed
  • Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer Clin Cancer Res. 2022 02 15; 28(4):576-584. . View in PubMed
  • Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control Nat Biomed Eng. 2021 11; 5(11):1348-1359. . View in PubMed
  • The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma Cancer Immunol Res. 2021 01; 9(1):75-88. . View in PubMed
  • Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity Mol Cancer Ther. 2021 01; 20(1):173-182. . View in PubMed
  • Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity Mol Ther. 2021 07 07; 29(7):2335-2349. . View in PubMed
  • STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor GrowthCell Metab. 2020 01 07; 31(1):148-161. e5. . View in PubMed
  • CAR T Cell Therapy Progress and Challenges for Solid Tumors Cancer Treat Res. 2020; 180:297-326. . View in PubMed
  • Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors Sci Transl Med. 2020 09 02; 12(559). . View in PubMed
  • Precision Medicine-Enabled Cancer Immunotherapy Cancer Treat Res. 2019; 178:189-205. . View in PubMed
  • PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine J Nucl Med. 2018 10; 59(10):1531-1537. . View in PubMed
  • Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer Oncoimmunology. 2018; 7(2):e1380764. . View in PubMed
  • Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells Front Immunol. 2018; 9:2268. . View in PubMed
  • Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain Clin Cancer Res. 2018 01 01; 24(1):95-105. . View in PubMed
  • Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer Clin Cancer Res. 2017 Jan 15; 23(2):478-488. . View in PubMed
  • Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance Mol Cancer Ther. 2017 11; 16(11):2516-2527. . View in PubMed
  • Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting Prostate. 2017 02; 77(2):123-144. . View in PubMed
  • L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice PLoS One. 2016; 11(1):e0146885. . View in PubMed
  • Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy N Engl J Med. 2016 12 29; 375(26):2561-9. . View in PubMed
  • Smart CARs engineered for cancer immunotherapy Curr Opin Oncol. 2015 Nov; 27(6):466-74. . View in PubMed
  • STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis Cancer Immunol Res. 2015 Aug; 3(8):864-870. . View in PubMed
  • CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells J Clin Invest. 2015 Jun; 125(6):2547. . View in PubMed
  • Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy Mol Ther. 2015 Apr; 23(4):757-68. . View in PubMed
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy Cancer Res. 2015 Mar 15; 75(6):950-62. . View in PubMed
  • CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation Eur J Immunol. 2015 Jan; 45(1):71-81. . View in PubMed
  • CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells J Clin Invest. 2014 Jul; 124(7):2977-87. . View in PubMed
  • Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression Mol Cell Biol. 2014 Jun; 34(11):2017-28. . View in PubMed
  • S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3 Cell Rep. 2014 Mar 27; 6(6):992-999. . View in PubMed
  • Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance Proc Natl Acad Sci U S A. 2013 Aug 06; 110(32):13079-84. . View in PubMed
  • CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer Cancer Res. 2013 May 01; 73(9):2782-94. . View in PubMed
  • Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma PLoS One. 2013; 8(12):e81657. . View in PubMed
  • S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites Cancer Cell. 2012 May 15; 21(5):642-654. . View in PubMed
  • In vivo imaging of intraprostatic-specific gene transcription by PET J Nucl Med. 2011 May; 52(5):784-91. . View in PubMed
  • The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res. 2010 Sep 15; 70(18):7042-52. . View in PubMed
  • Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels Mol Genet Metab. 2010 Sep; 101(1):66-75. . View in PubMed
  • Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy Blood. 2010 Feb 18; 115(7):1461-71. . View in PubMed
  • Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):260-8. . View in PubMed
  • A novel intracellular protein delivery platform based on single-protein nanocapsules Nat Nanotechnol. 2010 Jan; 5(1):48-53. . View in PubMed
  • Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor J Nucl Med. 2009 May; 50(5):757-64. . View in PubMed
  • Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis Cancer Res. 2008 Oct 01; 68(19):7828-37. . View in PubMed
  • ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia Blood. 2007 Apr 15; 109(8):3400-8. . View in PubMed
  • Calcium-dependent upregulation of E4BP4 expression correlates with glucocorticoid-evoked apoptosis of human leukemic CEM cells Biochem Biophys Res Commun. 2006 Jun 02; 344(2):491-9. . View in PubMed

Similar People